The light at the end of the tunnel for dry AMD and potential for other retinal diseases consists of a multiwavelength approach to stimulate cellular function
Clark E. Tedford tells The Ophthalmologist about his part in creating LumiThera, its flagship product and technology, and the company’s plans for the future
1
min read
False
Advertisement
False
Advertisement
Explore More in Ophthalmology
Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.